Guardant Health (GH)
(Delayed Data from NSDQ)
$21.40 USD
+0.79 (3.83%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.38 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.40 USD
+0.79 (3.83%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.38 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Zacks News
BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China
by Zacks Equity Research
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
U.S. Consumer Spending Bolsters Economic Growth: 5 Picks
by Zacks Equity Research
U.S. Consumer spending rises in November and with consumer sentiments' higher in December, these five stocks are a good buy.
Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.
ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study
by Zacks Equity Research
ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.
BioCryst Submits NDA for Hereditary Angioedema Candidate
by Zacks Equity Research
BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.
VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
by Zacks Equity Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
Guardant Health, Gap, GameStop, Microsoft and Sony highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Guardant Health, Gap, GameStop, Microsoft and Sony highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Guardant Health (GH)
by Kevin Cook
Cancer diagnostics provider just delivered 181% revenue growth and 18,500 tests to patients and labs
Top Ranked Momentum Stocks to Buy for December 6th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 6th
Spero Posts Preliminary Data on SPR720 for Pulmonary Disease
by Zacks Equity Research
Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Kirkland Lake Gold, Target and Guardant Health
by Zacks Equity Research
Zacks.com featured highlights include: Kirkland Lake Gold, Target and Guardant Health
Top Ranked Momentum Stocks to Buy for December 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 2nd
Top 3 Momentum Anomaly Stocks to Buy for Healthy Profits
by Zacks Equity Research
These stocks are currently witnessing short-term pullback in a bull market. So, this could just be the perfect entry point for investors who are looking to enhance their portfolio returns.
Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline
by Zacks Equity Research
Alkermes (ALKS) will acquire Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in milestone payments.
Guardant Health Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Guardant Health.
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for November 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 12th
Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Guardant Health (GH) closed at $70.96, marking a +0.45% move from the previous day.
Guardant Health (GH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.
Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
by Zacks Equity Research
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health